These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2121738)

  • 1. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.
    Chen G; Zeller WJ
    J Cancer Res Clin Oncol; 1990; 116(5):443-7. PubMed ID: 2121738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines.
    Chen G; Zeller WJ
    Cancer Lett; 1992 Oct; 67(1):27-33. PubMed ID: 1423242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin.
    Robichaud NJ; Fram RJ
    Chem Biol Interact; 1990; 76(3):333-42. PubMed ID: 2225234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.
    Chen G; Zeller WJ
    Cancer Chemother Pharmacol; 1993; 33(2):157-62. PubMed ID: 8261576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.
    Chen G; Zeller WJ
    Anticancer Res; 1994; 14(4A):1461-7. PubMed ID: 7979172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoresistance in rat ovarian tumours.
    Zeller WJ; Frühauf S; Chen G; Keppler BK; Frei E; Kaufmann M
    Eur J Cancer; 1991; 27(1):62-7. PubMed ID: 1826445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
    Andrews PA; Schiefer MA; Murphy MP; Howell SB
    Chem Biol Interact; 1988; 65(1):51-8. PubMed ID: 3345573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
    Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
    Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines.
    Chen G; Frei E; Zeller WJ
    Cancer Lett; 1989 Aug; 46(3):207-11. PubMed ID: 2766260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells.
    Andrews PA; Murphy MP; Howell SB
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):619-25. PubMed ID: 2714338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
    McLaughlin K; Stephens I; McMahon N; Brown R
    Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further characterization of acquired-resistance to Cisplatin in a rat ovarian tumor-cell line.
    Chen G; Hutter K; Zeller W
    Int J Oncol; 1992 Jul; 1(2):135-40. PubMed ID: 21584522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
    Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract]   [Full Text] [Related]  

  • 18. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
    Parekh H; Simpkins H
    Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin.
    Chen G; Todorov DK; Zeller WJ
    Cancer Lett; 1992 Feb; 62(2):173-7. PubMed ID: 1531781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.